PIK3CA and neoplasm: They showed a wide spectrum of activity against many tumor cell lines in vitro including those harboring PIK3CA mutations, PTEN and LKB deletion (Maira et al., 2008; Serra et al., 2008; Guillard et al., 2009; Hong et al., 2014; Yu et al., 2014).